Neumedicines Inc. Receives an Award of $8.3 Million From Biomedical Advanced Research and Development Authority (BARDA) for Continued Development of HemaMax as a Countermeasure to Acute Radiation Exposure

Published: Jun 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation medical countermeasure and as a hematological adjuvant cancer therapy (HACT), announces the award of $8.3 million from the Biomedical Advanced Research & Development Authority (BARDA) of the U.S. Department of Health and Human Services (DHHS) for the continued development of HemaMax™ (recombinant human interleukin 12 or rHuIL-12) for hematopoietic syndrome of acute radiation sickness (HSARS). This award is based on the exercise of Option 1 of the existing contract with BARDA for advanced development of HemaMax™.

Help employers find you! Check out all the jobs and post your resume.

Back to news